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Prognostic significance of high 
GFI1 expression in AML of normal 
karyotype and its association with a 
FLT3-ITD signature
Giacomo Volpe, David S. Walton, David E. Grainger, Carl Ward, Pierre Cauchy, Daniel 
Blakemore, Daniel J. L. Coleman, Peter N. Cockerill, Paloma Garcia & Jon Frampton
Growth Factor Independence 1 (GFI1) is a transcriptional repressor that plays a critical role during both 
myeloid and lymphoid haematopoietic lineage commitment. Several studies have demonstrated the 
involvement of GFI1 in haematological malignancies and have suggested that low expression of GFI1 
is a negative indicator of disease progression for both myelodysplastic syndromes (MDS) and acute 
myeloid leukaemia (AML). In this study, we have stratified AML patients into those defined as having 
a normal karyotype (CN-AML). Unlike the overall pattern in AML, those patients with CN-AML have a 
poorer survival rate when GFI1 expression is high. In this group, high GFI1 expression is paralleled by 
higher FLT3 expression, and, even when the FLT3 gene is not mutated, exhibit a FLT3-ITD signature of 
gene expression. Knock-down of GFI1 expression in the human AML Fujioka cell line led to a decrease in 
the level of FLT3 RNA and protein and to the down regulation of FLT3-ITD signature genes, thus linking 
two major prognostic indicators for AML.
The concept of disease stratification promises to provide great improvements in the diagnosis, prognosis, and 
treatment of cancer, but requires robust and readily measurable biomarkers in order to be feasible. In the case 
of haematological malignancies, much has been possible through traditional phenotypic categorisation and the 
identification of associated genetic mutations. More recently, genome wide approaches, both at the level of gene 
mutations and transcriptome analysis, have enabled refinement of the classification of haematological malignan-
cies, but there is still a great need to identify reliable molecular differences not only as prognostic indicators but 
also as potential therapeutic targets.
Acute myeloid leukaemia (AML) is a malignant myeloproliferative disease of the bone marrow accounting 
for ~10% of all haematological disorders1, 2. Currently, risk classification of AML with normal karyotype, rep-
resenting 50% of the cases, is based on molecular biomarkers including mutations in the genes encoding FLT3, 
NPM1, NRAS, KRAS, KIT and CEBPA3. FLT3 is a tyrosine kinase receptor that is expressed in early haematopoi-
etic cells and is essential for their proliferation and differentiation4, 5. FLT3 is known to be expressed at elevated 
levels on the AML blast cells in over 70% of AML patients and it is among the most commonly mutated genes 
in AML6. The mutations are typically internal tandem duplications within the juxta-membrane domain of the 
receptor (FLT3-ITD), occurring in 20–30% of AML cases7, 8. FLT3-ITD mutations lead to constitutive signalling 
and factor-independent cell survival and proliferation9, and are associated with adverse clinical outcome. The 
leukaemogenic effects of the FLT3-ITD mutations are reflected in a distinct gene regulation signature, which is 
characterised by up and down regulation of DNase I hypersensitive sites and genes encoding key haematopoietic 
regulators and functional proteins10.
Growth Factor Independence 1 (GFI1), a zinc-finger transcriptional repressor that plays several critical roles 
in haematopoietic lineage commitment and development11–13 is being increasingly associated with haematologi-
cal malignancies14–18. Mutations in GFI1 that lead to a dominant-negative loss of function have been reported in a 
number of patients with congenital neutropenia16, whilst investigation of single nucleotide polymorphisms (SNP) 
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associated with an increased predisposition towards AML led to the identification of a serine-asparagine substi-
tution in the N-terminal region of GFI1 (GFI136N)17. In line with these findings, Hönes et al. analysed a cohort of 
524 de novo AML cases and concluded that low expression of GFI1 is linked with an inferior prognosis18.
In this study we have further analysed publicly available AML data with respect to the link between GFI1 
expression and prognosis, but have stratified patients on the basis of the mutational status of their disease. This 
analysis has revealed that in cytogenetically normal AML (CN-AML) patients, high GFI1 expression predicts a 
significantly inferior overall survival. This higher GFI1 expression correlated with higher FLT3 levels and a gene 
expression profile reminiscent of that seen in AML with the FLT3-ITD mutation, thus suggesting an important 
molecular connection between these factors in CN-AML.
Results
CN-AML patients with high GFI1 expression have a worse clinical outcome. The analysis of AML 
gene profiling array data presented by Hönes et al.18 focused on the importance of low GFI1 expression as a 
marker of inferior outcome in AML/MDS patients. The authors of the latter study considered all patients in the 
cohort reported by Verhaak et al.19, encompassing a broad spectrum of mutations including gene fusions with 
core transcriptional activators or repressors. We were interested to know how patients with CN-AML might rep-
resent a distinct subset in terms of the mechanisms underpinning leukaemogenesis, in particular in relation to 
the importance of GFI1 and FLT3 expression, and FLT3 mutational status.
For our analysis, we took the same data set as described by Verhaak et al.19 and compared survival outcomes 
for the whole cohort with those for patients with CN-AML, distinguishing patients with low or high expression 
of GFI1. Our CN-AML category (n = 178) excluded patients displaying abnormal or unknown karyotype or 
classified in the M3 FAB subgroup, as those patients are treated differently. The distribution of GFI1 expres-
sion amongst all AML patients is not significantly different to that seen in the CN-AML subgroup (Fig. 1A). 
From the CN-AML group we selected the bottom 30% of the whole GFI1 expression range as low expressers 
(GFI1low, n = 27) and the top 30% as high expressers (GFI1high, n = 29), which closely encompasses the range of 
GFI1 expression surveyed by Hönes et al.18 (Fig. 1B). In this cohort, GFI1low patients demonstrated a significantly 
inferior outcome compared to the GFI1high patients (p = 0.027) (Fig. 1C).
Similar to the observations of Hönes et al.18 when considering the total AML cohort, analysis of the mutational 
status of our CN-AML subgroups revealed that FLT3-ITD and NPM1c mutations were more common in GFI1high 
samples, these being found in 59% (p = 0.0001) and 52% (p = 0.079) of patients, when compared to the GFI1low 
subgroup in which they were found in 11.2% and 29% of the patients, respectively (Table 1). No statistically signif-
icant difference was observed for IDH1, IDH2, NRAS, KRAS, CEBPA and EVI1 expression. Since the FLT3-ITD 
mutation is generally associated with higher FLT3 expression, we next analysed the abundance of FLT3 transcript 
and observed this to be higher in GFI1high samples (p = 0.0002, Fig. 1D). No differences between GFI1low and 
GFI1high groups were seen with respect to FAB classification, age, or sex (Table 1). Considering that FLT3-ITD 
is the poorest prognostic marker in CN-AML, we speculated that this could account for the inferior survival 
observed in the GFI1high patient subgroup. We therefore sub-classified the GFI1high CN-AML patients according 
to the presence or absence of FLT3-ITD. Surprisingly, GFI1high FLT3-WT patients (n = 10) still displayed lower 
overall survival (p = 0.0046) (Fig. 1E) and higher FLT3 expression (p = 0.000033) that is comparable to the levels 
seen in patients carrying FLT3-ITD mutations (Fig. 1F). Similar to the sub-cohort of CN-AML patients carrying 
FLT3-ITD mutations, no differences in the FAB classification, age or sex were observed.
High GFI1 expression corresponds with a FLT3-ITD gene expression signature in FLT3-WT 
CN-AML. It was recently reported that FLT3-ITD is associated with a distinct gene expression profile, the spe-
cific signature being defined as those genes expressed at least one log2-fold higher in FLT3-ITD AML compared 
to CD34+ peripheral blood stem cells (PBSC), excluding those genes linked to mature myeloid differentiation that 
are expressed in CD14+ bone marrow cells at a level twice as high in PBSC10. This FLT3-ITD AML gene expres-
sion signature incorporates 134 genes, which were further validated against the dataset from Verhaak et al.19.
We therefore investigated whether high GFI1 expression in the CN-AML FLT3-WT leukaemias corresponds 
to higher abundance of the FLT3-ITD molecular signature genes. Using the AML gene expression dataset of 
Verhaak et al.19, we determined the expression of the FLT3-ITD signature genes in FLT3-WT CN-AML patients 
and stratified these according to the level of GFI1 RNA. Strikingly, this analysis revealed that in GFI1high AML 
the expression of genes making up the FLT3-ITD signature was largely elevated compared to AML with low 
GFI1 expression (Fig. 2A). Further to validate these findings, we confirmed the association between high GFI1 
levels and FLT3-ITD signature genes in another independent CN-AML cohort from a study performed on 251 
CN-AML samples, reported by Kohlmann et al.20 (Fig. 1).
Known regulators of FLT3 are over expressed in GFI1high CN-AML. Recent reports have demon-
strated a mechanism for the Gfi1-dependent acceleration of K-Ras driven myeloproliferative disorders in mice 
through the over expression of HoxA9 and other AML-related genes15, 21, eventually leading to the development 
of AML. This study also revealed elevated expression of the HoxA9 partner proteins Meis1 and Pbx1, and of their 
known target genes Myb and Spi1/PU.1. Considering that these transcription factors, together with CEBPα, are 
among the main regulators of FLT3 activity in AML22–24, we next sought to determine whether high GFI1 lev-
els are associated with differences in their expression in CN-AML patients. Comparing GFI1high versus GFI1low 
FLT3-WT CN-AMLs, we found higher expression in the former of MYB (p = 0.0029), CEBPA (p = 0.0043), 
HOXA9 (p = 0.0052), HOXA7 (p = 0.0033), MEIS1 (p = 0.000043) and PBX3 (p = 0.0001), while lower abun-
dance was observed for PBX1 (p = 0.011) and PBX2 (p = 0.00004). No differences were observed in the levels of 
MEIS2 and PU.1 (Fig. 2B). The latter is unsurprising as we have previously shown that PU.1 is directly involved 
in regulating FLT3 in haematopoietic progenitor cells but not in leukaemic cells23–25. While the lower levels of 
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PBX1 and PBX2 observed in high GFI1 patients are in agreement with the findings presented by Horman et al.15, 
higher expression of HOXA9 and its partner MEIS1 are in contrast with their observations. This difference could 
be explained by the fact that our analysis was performed in CN-AML patients only, therefore excluding patients 
harbouring chromosomal translocations, such as those involving MLL, in which HOXA9 expression is often 
deregulated26, 27. To address this, we performed the same analysis using patient samples from the whole AML 
cohort, classified into GFI1 low and high expressers. In line with previous observations, this analysis revealed 
lower expression levels of HOXA9, HOXA7 and MEIS1 (Fig. 2B).
Reduction of GFI1 in AML cell lines leads to decreased expression of FLT3-ITD signature 
genes. In order to assess the significance of our observed correlation between GFI1 expression and the level 
of FLT3-ITD signature genes in FLT3-WT CN-AML, we next investigated whether manipulation of GFI1 expres-
sion in a human AML cell line would lead to corresponding changes in the expression of the FLT3-ITD signature 
Figure 1. High GFI1 expression associates with raised FLT3 expression and inferior survival in CN-AML 
patients. (A) Scatter plot representation of GFI1 expression for patient samples from the whole Verhaak et al.19 
dataset (WHOLE AML) or selected on the basis of having a normal karyotype (CN-AML). (B) Representation 
of GFI1low and GFI1high expression boundaries as reported by Hönes et al.18 (0–5% low expression, 60–100% 
high expression) and in the present study (0–30% low expression, 70–100% high expression). (C) Kaplan-Meyer 
representation of overall survival for CN-AML patients from the Verhaak et al.19 dataset subdivided in low 
and high GFI1 expressers. (D) Box plot representing FLT3 transcript levels in GFI1low versus GFI1high CN-AML 
patient samples. Statistical significance: ***< 0.001, **< 0.01, *< 0.05. (E) Kaplan-Meyer estimates of overall 
survival for GFI1low and GFI1high FLT3-WT CN-AML samples in comparison with FLT3-ITD CN-AML patients 
from the Verhaak et al.19 dataset. (F) Boxplot depicting FLT3 transcript levels in GFI1low and GFI1high FLT3-WT 
CN-AML in comparison with FLT3-ITD CN-AML samples.
www.nature.com/scientificreports/
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genes. First, we measured the relative expression of GFI1 RNA in human AML cell lines characterised by the 
expression of wild type FLT3 receptor, including KG1a, Kasumi-1, THP1, and Fujioka. Quantitative RT-PCR 
revealed that GFI1 is least expressed in KG1a and most highly expressed in Fujioka cells (Fig. 3A). To determine 
if higher expression of the FLT3-ITD signature genes also correlates with GFI1 level in these cells lines, we then 
tested the transcript abundance of the FLT3-ITD signature genes NFIX, FAM92A1, BIK, IGFBP2, LYRM1, IRX3, 
PBX3, PRTN3, AK2, CTSG, FLT3, ELANE and AZU1. Interestingly, this analysis demonstrated higher expression 
of most of these genes, with the exception of FAM92A1, in those cell lines with the highest expression of GFI1 
(Fig. 3B).
Next, we performed siRNA-mediated knockdown of GFI1 in the Fujioka line to determine if the highlighted 
FLT3-ITD signature genes were dependent on the high level of GFI1 expression in these cells. Fujioka cells were 
electroporated with siRNA targeting either GFI1 or a scrambled negative control. Cells were harvested 24 hours 
post transfection to assess GFI1 expression levels by quantitative RT-PCR, revealing a highly significant down 
regulation of both GFI1 RNA (p < 0.001) (Fig. 4A). Cells were additionally collected at 48 hours for preparation 
of protein extracts and assessment of GFI1 protein levels by immunoblotting (Fig. 4B). Cell counts performed 
every 24 hours post transfection revealed that GFI1 down regulation had no significant effect on cell growth 
(Fig. 4C). Fujioka cells were maintained in culture for 96 hours post transfection at which point the expression of 
several surface markers associated with myeloid differentiation was tested by immunofluorescence / flow cytom-
etry. CD34, CD38, CD11b, CD14, and CD56 showed no measurable differences (data not shown), whereas FLT3 
surface expression was significantly decreased (Fig. 4D). Importantly, analysis of the expression of FLT3-ITD 
signature genes demonstrated a reduction in the abundance of several of these, the most notable being NFIX, BIK, 
IGFBP2, LYRM1 PRTN3, AK2, CTSG, FLT3, ELANE, and AZU1 (Fig. 4E).
Discussion
In this study, we show that higher levels of GFI1 expression can be used to predict unfavourable outcome in AML 
patients with normal cytogenetics, and thereby provide a possible stratification for therapy choices. Additionally, 
we found that higher GFI1 levels are also associated with higher FLT3 expression and elevated levels of FLT3-ITD 
signature genes even in patients with non-mutated FLT3.
Compared to earlier findings by other groups, the way in which we have distinguished between CN-AML and 
AML with abnormal cytogenetics illustrates how stratification based on a single factor such as GFI1 expression 
can lead to quite different conclusions. Hence, Hönes et al.18 sub-fractioned AML patients purely according to 
GFI1 expression revealing that overall inferior survival associated with low GFI1 levels. In the present study we 
first classified AML based on karyotype, dividing them into abnormal karyotype only and CN-AML only and 
then sub-fractioning these two groups into low and high GFI1 expressers. In the first group we observed that low 
GFI1 expressers were indeed associated with inferior outcome, in agreement with findings reported previously. 
Strikingly, when the same criterion was applied to the CN-AML group, we observed that high GFI1 expressers 




(n = 29) p-value
Mutations
IDH1 1 4 0.1990
IDH2 3 2 0.4653
NPM1 8 15 0.0792
FLT3-ITD 3 17 0.0002
NRAS 3 1 0.2787
KRAS 2 0 0.2453
EVI1 2 0 0.2543
CEBPA 4 1 0.1544
FAB Classification
M0 1 2 1
M1 7 10 0.56
M2 6 3 0.2884
M4 4 4 1
M5 7 10 0.5678




Median age 48.33 46.27
Table 1. Genetic and phenotypic characteristics of the GFI1low and GFI1high leukaemias in the CN-AML 
category. The table shows data relating to the 56 patient AMLs included in the CN-AML sub group, including 
the occurrence of common specific leukaemia-associated mutations, the FAB categorisation, and the sex and 
age of the patients.
www.nature.com/scientificreports/
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We also considered how the status of FLT3 expression or mutation might correlate with the stratification. In 
their study of unfractionated AML Hönes et al.18 suggested that FLT3-ITD associates with high GFI1 levels and 
favourable outcome measures, which is a surprising finding given that FLT3-ITD is the most significant prog-
nostic factor in AML and is associated with unfavourable outcome. However, as we have discussed, patients from 
this cohort were not subcategorized based on karyotype, raising the possibility that GFI1 impacts on leukaemia 
in different ways according to the driver mutations. When we looked at the CN-AMLs we also observed an asso-
ciation of FLT3-ITD with the GFI1high group, suggesting that FLT3-ITD was responsible for the inferior outcome 
observed in those patients. To test this, we looked instead at only those CN-AML that had a wild type FLT3 status, 
again classifying into GFI1low versus GFI1high. This analysis showed that the overall survival of the GFI1high AML 
was much worse, and moreover, these AML exhibited a significantly higher expression of FLT3.
Several studies, mainly in mouse models, have addressed the role of GFI1 in haematological malignancies. 
In line with an association between high GFI1 expression and poor outcomes it has been reported that Gfi1 
cooperates with Pim-1 and Myc in the genesis of T-cell lymphoma28. High levels of GFI1 expression were also 
found to be important in accelerating T-cell proliferation and preventing induced cell death in Jurkat T-cells29. 
Figure 2. Analysis of FLT3-ITD signature genes and known FLT3 regulators in CN-AML (A) Histogram 
representing gene expression ratio of FLT3-ITD molecular signature in GFIhigh versus GFI1low FLT3-WT CN-
AML patient samples from the Verhaak dataset. (B) Analysis of expression levels of known regulators of FLT3 
activity in leukaemia, comparing GFI1low versus GFI1high FLT3-WT CN-AML samples (blue bars) or WHOLE 
AML samples (red bars). Statistical significance: ***< 0.001, **< 0.01, *< 0.05
www.nature.com/scientificreports/
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Furthermore, Khandanpour et al.21 reported a requirement for Gfi1 in the establishment and progression of 
murine B-cell lymphoma and T-cell acute lymphoblastic leukaemia driven by various genetic lesions, the ablation 
of Gfi1 leading to significant tumour regression and increased host survival in a p53-dependent manner30. In 
apparent contrast to these latter findings, the role of Gfi1 in the regulation of HoxA9, Meis1 and Pbx1 in murine 
myeloid cells appears to prevent predisposition to haematological malignancies, its loss-of-function decreasing 
the latency of KRas-driven MDS15. These observations were further supported by the identification of a SNP in 
the GFI1 gene that generates a variant protein (GFI1[36N]), which experimentally accelerated KRas-driven mye-
loproliferative disorders by inducing epigenetic changes at the HoxA9 locus21. Similarly, studies using a human-
ized GFI1 knockdown mouse model showed that lower GFI1 levels accelerate the progression of MLL-AF9- and 
NUP98-HoxD13-driven AML.
These contrasting observations from different model systems clearly imply that the functional consequences of 
GFI1 activity can be quite different and context dependent, and there is a need to investigate more broadly what 
mechanisms operate. For example, one could speculate that in AML involving translocations in major chromatin 
remodellers, such as in MLL-AF4 gene fusions, high levels of GFI1 might antagonise runaway activation while 
the converse would fail to compensate the latter, resulting in additionally impaired differentiation and thus con-
tributing towards more aggressive leukaemogenesis. In CN-AML however, GFI1 might play a more physiological 
role with higher expression corresponding to repression of alternative lineages, thus favouring differentiation and 
thus more manageable AML.
To gain an initial insight into the influence of high GFI1 expression in FLT3-WT CN-AML we sought to 
determine if there is any correspondence with the signature of gene expression that characterises FLT3-ITD AML. 
Interestingly, this analysis showed that, despite those samples having wild type FLT3, the molecular signature of 
FLT3-ITD was prominent in GFI1high cells. More importantly, in the attempt to validate the relevance of these 
findings, we observed that a number of the components of the FLT3-ITD molecular signature (IGFBP2, PRTN3, 
AK2, CTSG, ELANE and AZU1) were down regulated after siRNA-mediated silencing of GFI1 in Fujioka human 
AML cell line. This suggests that one of the main mechanisms of GFI1 leading to inferior outcome might directly 
or indirectly act through these genes.
Taken together, our results call for a more elaborate stratification of AML patients to ensure proper diagnosis 
and effective treatment and demonstrate that high GFI1 expression is a reliable and powerful prognostic indicator 
for CN-AML. Our findings also suggest that it will be fruitful to investigate in detail how GFI1 is linked to driver 
mutations, including those involving FLT3.
Materials and Methods
Patient profiling arrays. Log2 transformed, MASS normalised microarray expression data from Verhaak 
et al.19 and Kohlmann et al.20 were retrieved from GEO accession number GSE6891 and GSE15434, respectively. 
CN-AML patients reported in those cohorts were ranked according to their GFI1 expression into GFI1high (top 
30% of expression range) and GFI1low (bottom 30%). Gene expression fold changes were expressed as log2 ratios 
of GFIhigh/GFI1low gene expression levels. Up- and down-regulated genes were identified as those displaying log2 
fold change ≥ 1 and p < 0.05. For data from Cauchy et al.10, and gene expression levels and fold changes from 
Verhaak et al.19 and Kohlmann et al.20 were retrieved for the previously published 134-gene FLT3-ITD signature.
Figure 3. Expression analysis of a set of FLT3-ITD molecular signature genes in human AML cell lines (A) 
Scatter plot showing the relative abundance of GFI1 transcript in KG1A, Kasumi-1, THP1 and Fujioka human 
AML cell lines. (B) Histogram depicting the relative transcript abundance of FLT3-ITD signature component in 
the Fujioka cell line.
www.nature.com/scientificreports/
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AML cell lines. KG1A, Kasumi-1, THP1, and Fujioka human AML cell lines were grown in RPMI 1640 
medium supplemented with 10% foetal bovine serum, 50 u/ml penicillin, 50 µg/ml streptomycin, and 2mM 
L-Glutamine. Cells were maintained at 0.5 × 106 cells/ml and were washed with phosphate buffered saline solu-
tion between passages.
Transfections, cell viability assays, and flow cytometry analysis. In total, 5 × 106 Fujioka cells 
were electroporated with 300 nM of either GFI1 siRNA (s199938, Ambion – Life Technologies) or scrambled 
control siRNA (4390843 Silencer Select Negative Control #1) using the BIORAD Gene Pulser XCell (BIORAD, 
Hercules, California, US). Cell proliferation assays were performed in triplicate with Fujioka cells transfected with 
GFI1 siRNA and negative control. Cells were counted every 24 hours for 4 consecutive days and growth curves 
were obtained by quantifying the number of viable cells. Flow cytometry analysis was performed on transfected 
Fujioka cells stained using antibodies against CD34, CD38, CD11b, CD14, CD56, and FLT3. All the antibodies 
were purchased from eBioscience.
Figure 4. siRNA-mediated downregulation of GFI1 expression in Fujioka cells (A) GFI1 transcript abundance 
was determined by quantitative-PCR in cells transfected with GFI1 siRNA and negative control siRNA. Results 
are representative of 5 independent experiments. Statistical significance was calculated using student’s t-test. 
***< 0.001, **< 0.01, *< 0.05. (B) Immunoblot analysis of GFI1 protein in extracts from cells transfected 
with GFI1 siRNA and negative control siRNA. GAPDH was used as internal control. For detection of GFI1 
the membrane was cut into two just below the 46 KDa ladder mark to avoid detection of a cross-reacting non-
specific band at around 40 KDa. (C) Cell viability was calculated by counting transfected cells every 24 hours 
for 4 consecutive days. (D) Flow cytometric staining of transfected Fujioka cells with a labelled antibody against 
FLT3. (E) RNA quantification by q-PCR of FLT3-ITD molecular signature component 24 hours post siRNA 
transfection in Fujioka cells. Statistical significance was calculated using student’s t-test. ***< 0.001, **< 0.01, 
*< 0.05.
www.nature.com/scientificreports/
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Quantitative PCR and Western Blot. RNA extraction was performed 24 hours post siRNA transfec-
tion using RNeasy Mini kit (Qiagen) and first-strand cDNA synthesis was performed using standard protocols. 
Quantitative RT-PCR analysis of GFI1, FLT3, GAPDH, and the components of the FLT3-ITD molecular signature 
was performed using predesigned Taqman gene expression assays (Applied Biosystems). Total proteins obtained 
from Fujioka cells transfected with either GFI1 siRNA or scrambled control were used for Western Blot analysis. 
Antibodies were as follows: anti-GFI1 mouse monoclonal (1:500, Santa Cruz Biotechnology) and anti-GAPDH 
mouse monoclonal (1:10000 dilution, Abcam).
Data availability. All patient data described were obtained from publically available databases.
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